BOC-L-丙氨酸甲酯 | 28875-17-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-L-丙氨酸甲酯
• 中文别名: Boc-L-丙氨酸甲基酯；N-叔丁氧羰基-L-丙氨酸甲酯；N-Boc-L-丙氨酸甲酯；(S)-BOC-L-丙氨酸甲酯
• 英文名称: (S)-N-(tert-butoxycarbonyl)alanine methyl ester
• 英文别名: Boc-Ala-OMe；Boc-L-alanine methyl ester；methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 28875-17-4
• 化学式: C₉H₁₇NO₄
• mdl: MFCD00038513
• 分子量: 203.238
• InChiKey: GJDICGOCZGRDFM-LURJTMIESA-N

物化性质

• 熔点：
  32-35 °C(lit.)
• 沸点：
  278℃
• 密度：
  1.03 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  将贮藏器密封，放入一个紧密封装的容器中，并存放在阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-L-Alanine methyl ester
Synonyms: Boc-Ala-OMe

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-L-Alanine methyl ester
CAS number: 28875-17-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H17NO4
Molecular weight: 203.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Boc-Ala-Ome是丙氨酸的一种衍生物。

反应信息

• 作为反应物：
  描述：

  BOC-L-丙氨酸甲酯 在 RuCl2(η**(2)-P,N-3-diphenylphosphino-1-propylamine)2 氢气 、 sodium methylate 作用下， 以 四氢呋喃 为溶剂， 80.0 ℃ 、5.0 MPa 条件下， 反应 18.0h， 生成 4-methyl-2-oxazolidone
  参考文献：
  名称：

  ALCOHOL PRODUCTION METHOD BY REDUCING ESTER OF LACTONE WITH HYDROGEN

  摘要：

  提供的酒精生产方法包括以下步骤：使用以以下一般式（1）表示的钌配合物作为催化剂，通过氢气还原酯或内酯以产生相应的醇，而无需添加碱性化合物：RuH(X)(L1)(L2)n(1)其中X代表一价阴离子配体，L1代表至少具有一个配位膦基团和至少一个配位氨基团的四齿配体，或者具有一个配位膦基团和一个配位氨基团的双齿氨基膦配体，L2代表具有一个配位膦基团和一个配位氨基团的双齿氨基膦配体，n为0时，L1为四齿配体，n为1时，L1为双齿氨基膦配体。

  公开号：

  US20100063294A1
• 作为产物：
  描述：

  2-叔丁氧羰基氨基丙烯酸甲酯 在 Rh⁽¹⁺⁾*2CH₄O*C₄H₁₂B^(1-)*C₃₄H₄₀O₂P₂ 、 氢气 作用下， 以 甲醇 为溶剂， 22.0 ℃ 、100.0 kPa 条件下， 反应 0.07h， 以100%的产率得到BOC-L-丙氨酸甲酯
  参考文献：
  名称：

  α -芳基-和α-Carboxyamidoethylenes的实际不对称加氢由铑（I） - {1,2-双[（ø -叔-butoxyphenyl）（苯基）膦基]乙烷}

  摘要：

  铑（I） - {1,2-二[（ø -叔-butoxyphenyl）（苯基）膦基〕乙烷}的[Rh（I） - （叔卜-SMS-PHOS）]的催化剂体系显示优越的效率大系列α-酰胺基苯乙烯和α-酰胺基丙烯酸酯的氢化。在22°C的甲醇中，在1-10 bar的氢气下，常规操作可获得高达> 99.9％的对映异构体过量以及极高的反应速率。实例包括工业基材。

  DOI：

  10.1002/adsc.201200780
• 作为试剂：
  描述：

  1-(2-pyridyl)-1,2-dicarba-closo-dodecaborane(12) 、 1-[5-(2-methylphenyl)pyridin-2-yl]-o-carborane 在 ammonium cerium (IV) nitrate 、 二(三叔丁基膦)钯 、 BOC-L-丙氨酸甲酯 作用下， 以 1,2-二氯乙烷 为溶剂， 以48 %的产率得到
  参考文献：
  名称：

  室温下笼式 B-H/B-H 键的 Pd 催化氧化脱氢交叉偶联：双（邻碳硼烷）的合成

  摘要：

  开发了两种吡啶基邻碳硼烷的 B-H/B-H 键的高效 Pd 催化氧化脱氢交叉偶联，从而制备了 B(3)-B(6') 异偶联和 B(3)-B （6'）在室温下具有广泛底物范围的同源偶联双碳硼烷。

  DOI：

  10.1021/acs.inorgchem.2c01360

文献信息

• New reagent for the introduction of Boc protecting group to amines: Boc-OASUD
  作者：B. Leela Maheswara Rao、Shaik Nowshuddin、Anjali Jha、Murali K. Divi、M. N. A. Rao

  DOI：10.1080/00397911.2017.1366525

  日期：2017.11.17

  ABSTRACT A new reagent, tert-butyl (2,4-dioxo-3-azaspiro [5,5] undecan-3-yl) carbonate (Boc-OASUD) for the preparation of N-Boc-amino acids is described. The Boc-OASUD reacts with amino acids and their esters at room temperature in the presence of a base and gives N-Boc-amino acids and their esters in good yields and purity. Introduction of the Boc group takes place without racemization. The Boc-OASUD

  摘要描述了一种用于制备 N-Boc-氨基酸的新试剂叔丁基 (2,4-dioxo-3-azaspiro [5,5] undecan-3-yl) 碳酸酯 (Boc-OASUD)。Boc-OASUD 在室温下在碱存在下与氨基酸及其酯反应，并以良好的产率和纯度得到 N-Boc-氨基酸及其酯。Boc 基团的引入无需外消旋化。Boc-OASUD 是一种固体且更稳定，是二碳酸二叔丁酯的更好替代品，二碳酸二叔丁酯熔点低，由于稳定​​性差，必须在塑料容器中分配，而不是玻璃。图形概要
• NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE
  申请人：Kuriyama Wataru

  公开号：US20110237814A1

  公开（公告）日：2011-09-29

  The present invention relates to a ruthenium carbonyl complex that is represented by the following Formula (1): RuXY(CO)(L)  (1) (in the Formula (1), X and Y, which may be the same or different from each other, represent an anionic ligand and L represents a tridentate aminodiphosphine ligand which has two phosphino groups and a —NH— group), its production method, and a method for production of alcohols by hydrogenation-reduction of ketones, esters, and lactones using the complex as a catalyst. The ruthenium carbonyl complex of the invention has a high catalytic activity and it can be easily prepared and handled.

  本发明涉及一种由以下化学式（1）表示的钌羰基配合物： RuXY(CO)(L)  (1) （在化学式（1）中，X和Y可以相同也可以不同，代表一个阴离子配体，L代表一个三牙螯合胺二膦配体，具有两个膦基团和一个—NH—基团），以及其制备方法，以及利用该配合物作为催化剂通过酮、酯和内酯的加氢还原生产醇的方法。 本发明的钌羰基配合物具有高催化活性，且易于制备和处理。
• Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors
  作者：Toru Yamaguchi-Sasaki、Yunoshin Tamura、Yuya Ogata、Takanori Kawaguchi、Jun Kurosaka、Yutaka Sugaya、Kanako Iwakiri、Tsuyoshi Busujima、Ryo Takahashi、Naoko Ueda-Yonemoto、Eiji Tanigawa、Tomoko Abe-Kumasaka、Hiroyuki Sugiyama、Kosuke Kanuma

  DOI：10.1248/cpb.c19-00895

  日期：2020.4.1

  anti-RSV drugs. The pyrazolo[1,5-a]pyrimidine series of compounds containing a piperidine ring at the 2-position of the pyrazolo[1,5-a]pyrimidine scaffold are known as candidate RSV fusion (F) protein inhibitor drugs, such as presatovir and P3. The piperidine ring has been revealed to facilitate the formation of an appropriate dihedral angle between the pyrazolo[1,5-a]pyrimidine scaffold and the plane

  呼吸道合胞病毒（RSV）是下呼吸道感染的最常见原因之一，并且是成人和儿童的重要病原体。尽管已经批准了两种药物治疗RSV感染，但这些药物的低治疗指数已促使制药公司开发出安全有效的小分子抗RSV药物。在吡唑并[1,5-a]嘧啶支架的2-位上含有哌啶环的吡唑并[1,5-a]嘧啶系列化合物被称为候选RSV融合（F）蛋白抑制剂药物，例如普雷沙托韦和P3。已经揭示出哌啶环有助于在吡唑并[1，5-a]嘧啶支架和酰胺键平面之间形成适当的二面角，以发挥抗RSV活性。对新设计的具有无环链而不是哌啶环的化合物的分子动力学研究提出并证明了一系列新的吡唑并[1,5-a]嘧啶衍生物，例如带有1-甲基氨基丙基部分的9c，具有相似的二面角分布到presatovir中的那些。化合物9c表现出有效的抗RSV活性，其EC50值低于1 nM，与presatovir相似。随后对9c苯环的优化研究导致了有效的RSV F蛋白抑制剂14f，其EC50值为0
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• [EN] 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES<br/>[FR] COMPOSÉS DE 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018011160A1

  公开（公告）日：2018-01-18

  The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

  本发明涉及式(I)化合物或药用可接受的盐、对映异构体或非对映异构体，其中R1至R4如上所述。这些化合物可能用于治疗或预防乙型肝炎病毒感染。